Cleveland, Ohio 44106

  • Bipolar Disorder


The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (abilify) in children with subsyndromal symptoms of bipolar disorder who also have a bipolar parent and other family member with a mood disorder.

Study summary:

This will be a double-blind, placebo-controlled, parallel-arm, randomized clinical trial that will last up to 12 weeks. This placebo-controlled portion will be followed by a 6-week open label extension/stabilization phase. In order to be eligible for participation in the extension/stabilization phase, subjects must: 1) in the investigator's opinion have had no dose-limiting side effects likely to be attributable to APZ; 2) participated in the blinded portion of the clinical trial for a minimum of 4 weeks.


Inclusion Criteria: - Outpatients ages 5-17 years (inclusive) - Patients, who in the investigator's opinion have substantial symptoms of mania, depression, or both within the past 2 weeks such that treatment with a pharmacological agent is warranted - Currently meets DSM-IV criteria for either cyclothymia, or bipolar disorder not otherwise specified (BP NOS) based on the results of both a semi-structured diagnostic research assessment (K-SADS-PL supplemented with sections from the WASH-U K-SADS) (Geller et al., 2001; Kaufman et al., 1997) and a clinical interview with a child and adolescent psychiatrist. - Offspring of a parent with a bipolar spectrum disorder (based on the results of either the Mini International Neuropsychiatric Interview (MINI)(Sheehan et al., 1998) or the Family History Method (FH-RDC)(Andreasen et al., 1977) - Has another first or second degree relative with a mood disorder determined by the results of either the MINI or the FH-RDC - Has participated in at least 4 sessions of psychotherapy specifically focused on the symptoms/management of pediatric mood disorder and continues to have clinically significant symptomatology Exclusion Criteria: - Patients who have a history of intolerance to APZ at doses of 0.1mg/kg/day - Patients who have experienced a manic episode with documented treatment with APZ monotherapy at a dose of 0.2 mg/kg/day - Patients with an active neurological/medical disorder for which treatment with APZ would be contraindicated - Patients with clinical evidence of autistic disorder, Asperger's disorder, Rett's syndrome or other pervasive developmental disorder - Patients with clinical evidence of mental retardation - Patients who are known to be allergic or hypersensitive to aripiprazole - Patients who are unable to swallow pills/capsules - Patients for whom the need for hospitalization during the course of the study appears likely - Patients who have started a new psychotherapeutic intervention within less than 4 weeks of randomization - Patients who have a general medical or neurological condition (including clinically significant abnormalities on screening laboratories) that may be considered to be the etiology of the patient's mood disorder - Patients who have a general medical or neurological condition for which treatment with an atypical antipsychotic would be contraindicated (e.g. tardive dyskinesia) - Patients who have a general medical or neurological condition that could interfere with the interpretation of clinical response to APZ treatment - Patients taking psychotropic agents (other than psychostimulants) within one week of baseline (2 weeks for fluoxetine; 3 days for psychostimulants) - Patients with a suicide attempt requiring medical/psychiatric care within the past 6 months - Has met DSM-IV criteria for drug/alcohol abuse or dependence within the past 6 months - Females who are currently pregnant or lactating - Sexually active females, who in the investigators' opinion are not using an adequate form of birth control



Primary Contact:

Principal Investigator
Robert L Findling, MD
University Hospitals of Cleveland

Backup Contact:


Location Contact:

Cleveland, Ohio 44106
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.